Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Sorafenib 7Radiosurgery 6Bevacizumab 6pembrolizumab 4Oxaliplatin 4Cryosurgery 4atezolizumab 3Radiotherapy, Conformal 3Nivolumab 3Ipilimumab 3Fluorouracil 3Cyclophosphamide 3tremelimumab 2spartalizumab 2lenvatinib 2fludarabine 2Leucovorin 2Injections 2Gemcitabine 2Everolimus 2Epirubicin 2Doxorubicin 2Celecoxib 2Carboplatin 2Capecitabine 2yttrium chloride 1vofatamab 1toripalimab 1tocilizumab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liver Neoplasms × vofatamab × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡